Thursday, November 11, 2021 10:22:29 AM
Exactly. Like I have been saying all along. CytoDyn will own Amarex. They will footdrag but settle. Contract law is clear cut. It's also becoming clear Amarex could be colluding with 13d and PigFarma. This case could get really interesting.
So now we know the rest of the story. We also know Nader's overdraft for 13 dollars and 87 centavos Fourty Years Ago that most states considered a misdemeanor,,, oh it too has been settled!
LMAO. What's next? Oh, please, for the millionth time, no stat significant BS from the handcuffed trial which showed the highest and best chance of survival than anything thus far. Not significant for a pick and choose FDA that permits Pfizer to manipulate the trial data for their jab that they admit may well cause more harm...Myocarditis "Since April 2021, increased cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna), particularly in adolescents and young adults." With latest data showing the high probablility the drug does more harm than good. Oh, yes, that FDA. The FDA that ignores 87% survival ability when using Leronolimab over SOC killer protocol. That FDA. And what of 13devoid of reality?
Laughing. No one really takes this jail talk seriously. The 13Dismal dudes have nothing to offer but scandal hype. It's like reading The Mirror or the National Inquirer. Good for a laugh is about it, however, over worn are the Dailey Rag stories getting so much press time that any PR that hits must be attacked and twisted to the absurdity. The real jail time, if any, will come in the form of collusion and stock manipulation by 13Dogs. We got a little money, paid off and rearranged some debt, and can pay now to go forward and take care of business. HouseOfCards got it right, it does not change one fact of our trials or drug leronlimab. What it does show is elevated anxiety and desperation. Notice how the PPS is behaving now overall, it appears Short volume diminishing because of strong fundamentals like "CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival"... some of which can become hot news at any moment. Hello Brasilia.
Everything 13dbunked has banked on has gone sour, plus they ignore the FDA controversial actions in many other pharmaceutical companies, while acting as if they are correct in their dirty treatment of CytoDyn. LOL, talk about ignoring the facts. The connections between 13devoid of reality and Adam & Yikes et al will come out if the SEC/FBI do their job. It won't be our BOD or CEO with naked shorting and collusion on the laptop. Hello Amarex, I hear heavy knocking at the door, no, it sounds like pounding. Non performance of a contract is a slam dunk case and with other entanglements surely we are looking at RICO statutes kicking in. CytoDyn will own Amarex.
There's is only one reason our PPS is down, 13Dfibrilation with their Pig Pharma brethren. Pure and simple.
Let's bump it up to 300 Million shares! Go Nader my good man, stick it to them. $CYDY$
So now we know the rest of the story. We also know Nader's overdraft for 13 dollars and 87 centavos Fourty Years Ago that most states considered a misdemeanor,,, oh it too has been settled!
LMAO. What's next? Oh, please, for the millionth time, no stat significant BS from the handcuffed trial which showed the highest and best chance of survival than anything thus far. Not significant for a pick and choose FDA that permits Pfizer to manipulate the trial data for their jab that they admit may well cause more harm...Myocarditis "Since April 2021, increased cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna), particularly in adolescents and young adults." With latest data showing the high probablility the drug does more harm than good. Oh, yes, that FDA. The FDA that ignores 87% survival ability when using Leronolimab over SOC killer protocol. That FDA. And what of 13devoid of reality?
Laughing. No one really takes this jail talk seriously. The 13Dismal dudes have nothing to offer but scandal hype. It's like reading The Mirror or the National Inquirer. Good for a laugh is about it, however, over worn are the Dailey Rag stories getting so much press time that any PR that hits must be attacked and twisted to the absurdity. The real jail time, if any, will come in the form of collusion and stock manipulation by 13Dogs. We got a little money, paid off and rearranged some debt, and can pay now to go forward and take care of business. HouseOfCards got it right, it does not change one fact of our trials or drug leronlimab. What it does show is elevated anxiety and desperation. Notice how the PPS is behaving now overall, it appears Short volume diminishing because of strong fundamentals like "CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival"... some of which can become hot news at any moment. Hello Brasilia.
Everything 13dbunked has banked on has gone sour, plus they ignore the FDA controversial actions in many other pharmaceutical companies, while acting as if they are correct in their dirty treatment of CytoDyn. LOL, talk about ignoring the facts. The connections between 13devoid of reality and Adam & Yikes et al will come out if the SEC/FBI do their job. It won't be our BOD or CEO with naked shorting and collusion on the laptop. Hello Amarex, I hear heavy knocking at the door, no, it sounds like pounding. Non performance of a contract is a slam dunk case and with other entanglements surely we are looking at RICO statutes kicking in. CytoDyn will own Amarex.
There's is only one reason our PPS is down, 13Dfibrilation with their Pig Pharma brethren. Pure and simple.
Let's bump it up to 300 Million shares! Go Nader my good man, stick it to them. $CYDY$
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
